Avestar Capital’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $731K | Buy |
3,730
+26
| +0.7% | +$5.05K | 0.05% | 279 |
|
|
2025
Q4 | $643K | Sell |
3,704
-1,076
| -23% | -$196K | 0.04% | 292 |
|
|
2025
Q3 | $911K | Buy |
4,780
+727
| +18% | +$129K | 0.06% | 237 |
|
|
2025
Q2 | $728K | Buy |
4,053
+32
| +0.8% | +$5.56K | 0.05% | 266 |
|
|
2025
Q1 | $680K | Sell |
4,021
-410
| -9% | -$67.4K | 0.06% | 253 |
|
|
2024
Q4 | $668K | Sell |
4,431
-1,857
| -30% | -$289K | 0.06% | 236 |
|
|
2024
Q3 | $976K | Buy |
6,288
+71
| +1% | +$10.6K | 0.1% | 160 |
|
|
2024
Q2 | $851K | Sell |
6,217
-6,933
| -53% | -$949K | 0.09% | 171 |
|
|
2024
Q1 | $1.75M | Buy |
13,150
+4,014
| +44% | +$521K | 0.18% | 111 |
|
|
2023
Q4 | $1.26M | Sell |
9,136
-1,274
| -12% | -$167K | 0.14% | 98 |
|
|
2023
Q3 | $1.27M | Buy |
10,410
+1,477
| +17% | +$197K | 0.18% | 78 |
|
|
2023
Q2 | $1.26M | Sell |
8,933
-438
| -5% | -$60.4K | 0.2% | 63 |
|
|
2023
Q1 | $1.33M | Sell |
9,371
-1,270
| -12% | -$182K | 0.24% | 58 |
|
|
2022
Q4 | $1.66M | Buy |
10,641
+94
| +0.9% | +$13.5K | 0.3% | 58 |
|
|
2022
Q3 | $1.29M | Buy |
10,547
+2,941
| +39% | +$387K | 0.33% | 52 |
|
|
2022
Q2 | $1.01M | Buy |
7,606
+2,307
| +44% | +$314K | 0.25% | 65 |
|
|
2022
Q1 | $725K | Buy |
5,299
+510
| +11% | +$71.1K | 0.12% | 167 |
|
|
2021
Q4 | $829K | Buy |
4,789
+1,536
| +47% | +$234K | 0.1% | 185 |
|
|
2021
Q3 | $473K | Buy |
3,253
+7
| +0.2% | +$1.02K | 0.06% | 282 |
|
|
2021
Q2 | $428K | Hold |
3,246
| – | – | 0.06% | 281 |
|
|
2021
Q1 | $427K | Hold |
3,246
| – | – | 0.1% | 198 |
|
|
2020
Q4 | $387K | Sell |
3,246
-20
| -0.6% | -$2.44K | 0.11% | 176 |
|
|
2020
Q3 | $406K | Hold |
3,266
| – | – | 0.13% | 131 |
|
|
2020
Q2 | $372K | Hold |
3,266
| – | – | 0.16% | 121 |
|
|
2020
Q1 | $262K | Sell |
3,266
-24
| -0.7% | -$2.48K | 0.14% | 126 |
|
|
2019
Q4 | $351K | Buy |
3,290
+2
| +0.1% | +$209 | 0.2% | 107 |
|
|
2019
Q3 | $352K | Buy |
3,288
+2
| +0.1% | +$205 | 0.22% | 92 |
|
|
2019
Q2 | $332K | Buy |
3,286
+9
| +0.3% | +$865 | 0.21% | 72 |
|
|
2019
Q1 | $293K | Buy |
3,277
+7
| +0.2% | +$607 | 0.19% | 73 |
|
|
2018
Q4 | $271K | Buy |
3,270
+29
| +0.9% | +$2.72K | 0.19% | 80 |
|
|
2018
Q3 | $349K | Hold |
3,241
| – | – | 0.2% | 69 |
|
|
2018
Q2 | $356K | Hold |
3,241
| – | – | 0.23% | 71 |
|
|
2018
Q1 | $325K | Hold |
3,241
| – | – | 0.21% | 66 |
|
|
2017
Q4 | $319K | Buy |
+3,241
| New | +$307K | 0.24% | 59 |
|
Other funds holding DGX
VCM
VPM
EIG
Avestar Capital's DGX Position: Q1 2026 in Review
Avestar Capital increased its Quest Diagnostics (DGX) stake by 0.7% in Q1 2026, buying an estimated $5.05K and bringing the position to 3,730 shares worth $731K. The position accounts for 0.05% of the portfolio, ranked #279.
Avestar Capital first reported a position in DGX in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.75M in Q1 2024. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Avestar Capital held 3,730 shares of Quest Diagnostics worth $731K as of Q1 2026.
- Avestar Capital bought 26 Quest Diagnostics shares in Q1 2026, an estimated $5.05K.
- Quest Diagnostics made up 0.05% of Avestar Capital's portfolio in Q1 2026, its #279 holding.
- Avestar Capital first reported a position in Quest Diagnostics in Q4 2017 and has held it in 34 quarters since.
- Avestar Capital's Quest Diagnostics position peaked at $1.75M in Q1 2024.
- 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.